Sickle Cell Disease
Eight important updates for World Sickle Cell Day
World Sickle Cell Day is observed each year on June 19.
FDA lifts hold on trials of gene therapies for sickle cell disease, beta-thalassemia
Poor lung function linked to fetal death among pregnant women with sickle cell disease
Pregnant women with sickle cell disease who had poor baseline gestational pulmonary function had significantly greater risk for fetal death, according to study results published in American Journal of Hematology.
Gene therapy for sickle cell disease shows curative potential
Three patients with sickle cell disease who received the investigational gene therapy ARU-1801 achieved and maintained normal hemoglobin levels, according to early results of a phase 1/phase 2 trial.
FDA approves Ferriprox for transfusional iron overload due to sickle cell disease
The FDA approved deferiprone for treatment of children or adults with transfusional iron overload due to sickle cell disease or other anemias.
Transplant increases survival for patients with kidney failure due to sickle cell disease
Patients with sickle cell disease-related kidney failure experienced similar reductions in mortality following transplantation as those whose kidney failure stemmed from other causes, according to researchers from Johns Hopkins.
Top in hem/onc: Sickle cell gene therapy, primary care in cancer centers
Last week, bluebird bio suspended clinical trials with its LentiGlobin product for sickle cell disease due to reported cases of hematologic malignancies among patients who received the treatment. It was the top story in hematology/oncology.
Celebrating Black Pioneers of Medicine
The Association for the Study of African American Life and History instituted an annual celebration and recognition of Black history in 1926.
Manufacturer suspends clinical trials for gene therapy to treat sickle cell disease
Gene therapy developer bluebird bio suspended clinical trials using its LentiGlobin product for sickle cell disease due to reported cases of hematologic malignancies among patients who received the treatment.
Sickle cell trait not tied to higher risk for MI, CHD in Black individuals
Sickle cell trait was not associated with increased risk for MI or CHD in Black individuals, according to a cohort study published in JAMA Network Open.